Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.15 as the latest value for Q3 2024.

  • Quarterly EPS (Weighted Average and Diluted) fell 7.14% to -$0.15 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$0.49 through Sep 2024, up 22.22% year-over-year, with the annual reading at -$0.59 for FY2024, 1.72% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2024 was -$0.15 at Crescent Biopharma, up from -$0.16 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.04 in Q1 2024, with the low at -$0.34 in Q4 2020.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.21, with a median of -$0.18 recorded in 2022.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 76.47% in 2024, while the deepest fall reached 23.08% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.34 in 2020, then increased by 3.05% to -$0.33 in 2021, then skyrocketed by 42.42% to -$0.19 in 2022, then increased by 26.32% to -$0.14 in 2023, then decreased by 7.14% to -$0.15 in 2024.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.15, -$0.16, and -$0.04 for Q3 2024, Q2 2024, and Q1 2024 respectively.